Literature DB >> 23761169

AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of β-catenin/Wnt signaling.

Zhibo Xia1, Ping Wei, Heng Zhang, Zhiming Ding, Lixuan Yang, Zhengsong Huang, Nu Zhang.   

Abstract

UNLABELLED: Glioma-initiating cells (GIC), which are characterized by their self-renewal capacity and tumorigenicity, were recently identified as a highly tumorigenic subpopulation of glioblastoma multiforme and are considered responsible for glioblastoma recurrence and chemo/radiation resistance. Previously, it was revealed that Wnt signaling activation is critical to the self-renewal of GICs. However, the molecular mechanism underlying the high expression of β-catenin, the key transcription factor of the Wnt signaling pathway, remains elusive. In this investigation, it was determined that aurora kinase A (AURKA) regulates the self-renewal and tumorigenicity of GICs by stabilizing β-catenin. In GICs, AURKA directly interacts with AXIN and disrupts the AXIN/GSK3β/β-catenin destruction complex and stabilizes β-catenin, thereby activating Wnt signaling to promote self-renewal. Stable knockdown of AURKA destabilizes β-catenin by increasing phosphorylated β-catenin bound to AXIN and suppresses Wnt signaling, which inhibits the ability of GICs to self-renew. This effect is rescued by expression of an AURKA kinase dead mutant, D274A, which lacks the ability to phosphorylate GSK3β, indicating that stabilization of β-catenin by AURKA in GICs is independent from phosphorylation of GSK3β. Functional experiments confirm that inhibition of AUKRA in GICs could suppress their "stemness," self-renewal ability, and tumorigenicity both in vitro and in vivo, and these effects could be rescued by stabilized β-catenin mutant. These findings indicate that AURKA competes away the binding of AXIN from β-catenin, induces β-catenin stabilization, and activates Wnt signaling in GICs. IMPLICATIONS: AURKA kinase inhibition could effectively attenuate Wnt signaling, thereby inhibiting the self-renewal and tumorigenicity of GICs, and may be a novel target for glioblastoma treatment strategies. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761169     DOI: 10.1158/1541-7786.MCR-13-0044

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

1.  Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles.

Authors:  Gabriela D A Guardia; Bruna R Correa; Patricia Rosa Araujo; Mei Qiao; Suzanne Burns; Luiz O F Penalva; Pedro A F Galante
Journal:  NPJ Genom Med       Date:  2020-01-16       Impact factor: 8.617

2.  Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Authors:  C Kurokawa; H Geekiyanage; C Allen; I Iankov; M Schroeder; B Carlson; K Bakken; J Sarkaria; J A Ecsedy; A D'Assoro; B Friday; E Galanis
Journal:  J Neurooncol       Date:  2016-11-05       Impact factor: 4.130

3.  miR-155 contributes to the progression of glioma by enhancing Wnt/β-catenin pathway.

Authors:  Zhiyong Yan; Shusheng Che; Jianpeng Wang; Yingbing Jiao; Chao Wang; Qinghai Meng
Journal:  Tumour Biol       Date:  2015-02-12

4.  Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.

Authors:  Masayuki Komatsu; Kanako Nakamura; Takashi Takeda; Fumiko Chiwaki; Kouji Banno; Daisuke Aoki; Fumitaka Takeshita; Hiroki Sasaki
Journal:  Oncogene       Date:  2022-03-07       Impact factor: 9.867

5.  β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Authors:  Ruhee Dere; Ashley Lyn Perkins; Tasneem Bawa-Khalfe; Darius Jonasch; Cheryl Lyn Walker
Journal:  J Am Soc Nephrol       Date:  2014-10-13       Impact factor: 10.121

6.  Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.

Authors:  Liang Xu; Ye Chen; Anand Mayakonda; Lynnette Koh; Yuk Kien Chong; Dennis L Buckley; Edwin Sandanaraj; See Wee Lim; Ruby Yu-Tong Lin; Xin-Yu Ke; Mo-Li Huang; Jianxiang Chen; Wendi Sun; Ling-Zhi Wang; Boon Cher Goh; Huy Q Dinh; Dennis Kappei; Georg E Winter; Ling-Wen Ding; Beng Ti Ang; Benjamin P Berman; James E Bradner; Carol Tang; H Phillip Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-15       Impact factor: 11.205

7.  Expression profiles of histone modification genes in gastric cancer progression.

Authors:  Seda Orenay-Boyacioglu; Elmas Kasap; Emre Gerceker; Hakan Yuceyar; Ufuk Demirci; Fahri Bilgic; Mehmet Korkmaz
Journal:  Mol Biol Rep       Date:  2018-09-24       Impact factor: 2.316

8.  Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.

Authors:  Yangchun Xie; Shan Zhu; Meizuo Zhong; Manhua Yang; Xiaofan Sun; Jinbao Liu; Guido Kroemer; Michael Lotze; Herbert J Zeh; Rui Kang; Daolin Tang
Journal:  Gastroenterology       Date:  2017-07-29       Impact factor: 22.682

9.  Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.

Authors:  Nan Li; Dustin J Maly; Yvan H Chanthery; Daniel W Sirkis; Jean L Nakamura; Mitchel S Berger; C David James; Kevan M Shokat; William A Weiss; Anders I Persson
Journal:  Mol Cancer Ther       Date:  2014-12-18       Impact factor: 6.261

10.  Selecting biologically informative genes in co-expression networks with a centrality score.

Authors:  Francisco J Azuaje
Journal:  Biol Direct       Date:  2014-06-19       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.